OBJECTIVE: This study aimed to compare @entity34 ( @entity34 ) among @entity1 treated with @entity2239 and chemotherapy, two commonly-used treatments for hormone-receptor-positive/ @entity1 -epidermal-growth-factor-receptor-2-negative (HR+/ @entity1722 -) metastatic @entity0 (mBC). METHODS: Postmenopausal @entity1 with HR+/ @entity1722 - mBC who initiated >= 1 new line of therapy for mBC during 7/20/2012-3/31/2014 after a non-steroidal-aromatase-inhibitor were identified from MarketScan and PharMetrics databases (2002Q1-2014Q2) using a claims-based algorithm. @entity1 were classified into treatment groups by regimen and line of therapy, and were followed until discontinuation of therapy, end of insurance eligibility, or data cut-off (06/30/2014). Discontinuation was defined as a treatment gap of >= 60 days; @entity1 who did not discontinue were censored at the end of follow-up. @entity34 was compared between @entity2239 , chemotherapy, and @entity416 monotherapy using Kaplan-Meier analyses and multivariable Cox models adjusting for line of therapy, age, insurance, de novo mBC diagnosis, prior use of chemotherapy for mBC, sites of metastases, and Charlson comorbidity index. RESULTS: Across the first four lines of therapies for mBC, a total of 940 @entity2239 , 3,410 chemotherapy, and 721 @entity416 monotherapy regimens were included. Based on the different lines of therapies, the median @entity34 ranged from 5.5 to 7.2 months for @entity2239 , 4.3 to 4.7 months for chemotherapy, and 3.5 to 6.0 months for @entity416 monotherapy. Pooling all lines of therapies, @entity2239 was associated with significantly longer @entity34 compared to chemotherapy (multivariable-adjusted hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.62-0.76) or @entity416 monotherapy (multivariable-adjusted HR = 0.73, 95% CI: 0.64-0.83). Longer @entity34 was consistently observed for @entity2239 for each line of therapy. LIMITATIONS: Proxies used for identifying HR+/ @entity1722 - mBC and treatment line, lack of certain clinical factors in claims data, generalizability limited to commercially-insured @entity1 in the US. CONCLUSIONS: This study found that HR+/ @entity1722 - mBC @entity1 receiving @entity2239 experienced significantly longer @entity34 than those receiving chemotherapy overall or @entity416 monotherapy.

Time on treatment of @entity2239 and chemotherapy among postmenopausal @entity1 with HR+/ XXXX - metastatic @entity0 : A retrospective claims study in the US.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'human', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus'] @entity1722 :: ('2064', 'Gene') :: ['HER2'] @entity34 :: ('MESH:D016609', 'Disease') :: ['time on treatment', 'TOT']
@entity1722 :: (2064,Gene) :: ['HER2']
